Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04103060
Recruitment Status : Completed
First Posted : September 25, 2019
Last Update Posted : November 24, 2020
Information provided by (Responsible Party):
Dermavant Sciences, Inc. ( Dermavant Sciences GmbH )

Brief Summary:
This is a phase 2a, randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, and systemic exposure of cerdulatinib gel, 0.37% in adults with vitiligo

Condition or disease Intervention/treatment Phase
Vitiligo Drug: Cerdulatinib 0.37% gel Drug: Vehicle gel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
Actual Study Start Date : September 27, 2019
Actual Primary Completion Date : November 3, 2020
Actual Study Completion Date : November 3, 2020

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Vitiligo
MedlinePlus related topics: Vitiligo

Arm Intervention/treatment
Experimental: Cerdulatinib 0.37% gel
Cerdulatinib 0.37% gel applied topically twice daily
Drug: Cerdulatinib 0.37% gel
Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
Other Name: DMVT-502

Placebo Comparator: Vehicle gel
Vehicle gel applied topically twice daily
Drug: Vehicle gel
Vehicle gel applied topically twice daily for 6 weeks

Primary Outcome Measures :
  1. Vital signs [ Time Frame: Baseline through Week 7 ]
    Body temperature, blood pressure, pulse (heart rate), and breathing rate (respiratory rate)

  2. Laboratory Values [ Time Frame: Baseline through Week 7 ]
    Clinically significant abnormal lab values

  3. Adverse Events [ Time Frame: Baseline through Week 7 ]
    Frequency, severity, and duration of adverse events

  4. Local Tolerability Scale Score [ Time Frame: Baseline, Week 2, Week 4, Week 6, and Week 7 ]
    Assessment of local site investigational product administration

Secondary Outcome Measures :
  1. Concentration of cerdulatinib [ Time Frame: Days 1, 15, 29 and 43 ]
    Plasma concentration

  2. Blister fluid biomarker concentration [ Time Frame: Baseline and Week 6 ]
    From active treated lesions and untreated nonlesional skin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects age 18 and older with a confirmed clinical diagnosis of vitiligo for at least 3 months, including ≥0.5% to ≤30% BSA involvement.
  • Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study
  • Capable of giving informed consent

Exclusion Criteria:

  • Diagnosis of segmental vitiligo
  • Subjects with concurrent conditions or history of other diseases (e.g., current or chronic history of liver disease) that could affect the safety of the subject or the implementation of this study
  • Use of any prohibited medication within the indicated period before the first dose of study drug
  • Pregnant or lactating females
  • Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 8 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's vitiligo
  • The subject has received an investigational product within the following time period prior to the first dosing day: 4 weeks or 5 half-lives (whichever is longer).
  • Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory test value abnormality that will affect the health of the subject or interfere with interpretation of the results
  • History of sensitivity to the study drug, or components thereof or a history of drug or other allergy that contraindicates the subject's participation in the study;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04103060

Layout table for location information
United States, California
Dermavant Investigational Site
Irvine, California, United States, 92617
United States, Massachusetts
Dermavant Investigational Site
Worcester, Massachusetts, United States, 01605
Sponsors and Collaborators
Dermavant Sciences GmbH
Layout table for investigator information
Study Director: Michael McLaughlin Dermavant Sciences GmbH
Layout table for additonal information
Responsible Party: Dermavant Sciences GmbH Identifier: NCT04103060    
Other Study ID Numbers: DMVT-502-2101
First Posted: September 25, 2019    Key Record Dates
Last Update Posted: November 24, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pigmentation Disorders
Skin Diseases